Breaking News

Tweet TWEET

MdxHealth (TM) : MDxHealth Shareholder Transparency Notifications

      MdxHealth (TM) : MDxHealth Shareholder Transparency Notifications

Regulated information


IRVINE, CA, and LIEGE,  BELGIUM, July 9, 2013  - MDxHealth SA (NYSE  Euronext: 
MDXH), a leading molecular diagnostic company that develops and commercializes
epigenetic tests to support  the diagnosis and  treatment of cancer  patients, 
announced today that it received the following notifications of significant
shareholdings, in  accordance with  the Belgian  Act of  May 2,  2007 on  the 
disclosure of significant shareholdings  in listed companies,  as a result  of 
the capital increase completed on June 25, 2013.

The shareholder notifications received following the completion of the capital
increase are:

Shareholdings after actively crossing the transparency threshold:

  *Biovest Comm.VA.,  the investment  vehicle of  Rudi Mariën,  has  informed 
    MDxHealth that its participation in MDxHealth crossed the threshold of 15%
    of the outstanding  shares on  June 25,  2013. Biovest  Comm.VA. now  owns 
    17.97% of the outstanding shares of MDxHealth.

  *Valiance  Asset   Management  Ltd   has   informed  MDxHealth   that   its 
    participation in MDxHealth, through the  different funds that it  manages, 
    crossed the threshold of 15% of  the outstanding shares on June 25,  2013. 
    Valiance Asset Management  Ltd now  controls 18.88% of  the voting  rights 
    attached to the outstanding shares of MDxHealth.

  *Petercam NV has  informed MDxHealth that  its participation in  MDxHealth, 
    through the different funds that it  manages, crossed the threshold of  3% 
    of the outstanding shares on June 25, 2013. Petercam NV now controls 4.41%
    of the voting rights attached to the outstanding shares of MDxHealth.

  *Life Sciences  Partners  Fund  II  BV  has  informed  MDxHealth  that  its 
    participation in MDxHealth fell below  the minimum statutory threshold  of 
    3% of the outstanding shares on June 25, 2013.

  *ING Group NV has  informed MDxHealth that  its participation in  MDxHealth 
    fell below the minimum statutory threshold of 3% of the outstanding shares
    on June 25, 2013. 

Shareholdings after passively crossing the transparency threshold:

  *IDInvest  Partners  has  informed  MDxHealth  that  its  participation  in 
    MDxHealth fell  below  the  minimum  statutory  threshold  of  3%  of  the 
    outstanding shares on June 25, 2013.

As per July 9, 2013, following the recent capital increase, MDxHealth had  EUR 
24,427,340.34 in cash and cash equivalents.

About MDxHealth^®
MDxHealth is a molecular diagnostics company that develops and  commercializes 
advanced epigenetic tests for cancer assessment and the personalized treatment
of  patients.  The  Company's  first  commercial  product,  ConfirmMDx^TM  for 
Prostate Cancer,  has been  shown  to help  distinguish  patients who  have  a 
true-negative biopsy  from those  who may  have undetected  cancer.  MDxHealth 
helps to address  a large  and growing unmet  medical need  for better  cancer 
diagnosis and treatment  information. The company  has a proprietary  platform 
and a  strong  epigenetic  product  pipeline focused  on  the  development  of 
products for prostate, brain and lung cancers. The company is based in Irvine,
California  with  a  European  headquarters   in  Liege,  Belgium.  For   more 
information visit MDxHealth's website at www.mdxhealth.com.

Contacts :

MDxHealth            MDxHealth Media Contact
Dr. Jan Groen        Mike Sinclair
CEO                  Halsin Partners
US: +1 949 812 6979  UK: +44 20 7318 2955
BE: +32 4 364 20 70  Cell: +44 7968 022075
info@mdxhealth.com  msinclair@halsin.com 

This press  release contains  forward-looking  statements and  estimates  with 
respect to the anticipated future performance  of MDxHealth and the market  in 
which it operates. Such statements and estimates are based on assumptions  and 
assessments of known and unknown risks, uncertainties and other factors, which
were deemed reasonable  but may  not prove to  be correct.  Actual events  are 
difficult to predict, may  depend upon factors that  are beyond the  company's 
control, and  may turn  out to  be materially  different. MDxHealth  expressly 
disclaims any obligation to update any such forward-looking statements in this
release to reflect any change in  its expectations with regard thereto or  any 
change in events, conditions or circumstances  on which any such statement  is 
based unless  required by  law or  regulation. This  press release  does  not 
constitute an offer or  invitation for the sale  or purchase of securities  or 
assets of MDxHealth  in any jurisdiction.  No securities of  MDxHealth may  be 
offered or sold within the United  States without registration under the  U.S. 
Securities Act  of  1933, as  amended,  or  in compliance  with  an  exemption 
therefrom, and in accordance with any applicable U.S. securities laws.



NOTE: The MDxHealth logo, MDxHealth, ConfirmMDx and PredictMDx are  trademarks 
or registered trademarks  of MDxHealth  SA. All other  trademarks and  service 
marks are the property of their respective owners.

To access the PDF version, please click here

------------------------------------------------------------------------------

This announcement is distributed by Thomson Reuters on behalf of Thomson
Reuters clients.

The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and other
applicable laws; and
(ii) they are solely responsible for the content, accuracy and originality of
the
information contained therein.

Source: MdxHealth (TM) via Thomson Reuters ONE
HUG#1715289
 
Press spacebar to pause and continue. Press esc to stop.